Breaking News
March 20, 2018 - Epidural stimulation can safely, effectively normalize blood pressure in patients with SCI
March 20, 2018 - ‘Fast track’ project shows promising results in cancer whole genome analyses
March 20, 2018 - Advanced insulin pump system can also manage type 1 diabetes in children, study shows
March 20, 2018 - Flu risk less on flights if in a window seat finds study
March 20, 2018 - Sarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53
March 20, 2018 - Post-Transplant Fatty Liver Disease on the Rise
March 20, 2018 - New mutation linked to ovarian cancer can be passed down through dad
March 20, 2018 - Scotland study aims to offer precise diagnoses for people with rare genetic diseases
March 20, 2018 - Stem cell treatment may help rejuvenate ovaries, avoid effects of premature menopause
March 20, 2018 - FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
March 20, 2018 - Death Strikes Young in RA
March 20, 2018 - Quiescent cells also mutate
March 20, 2018 - Stem cell-derived ocular cells treat severe AMD
March 20, 2018 - Mediterranean diet appears to be good for postmenopausal women’s bones and muscles
March 20, 2018 - Scientists discover rare childhood liver cancer’s ability to metastasize to the brain
March 20, 2018 - Treating metastatic breast cancer with immunotherapy
March 20, 2018 - The 5:2 diet could have beneficial impact on important risk markers for cardiovascular disease
March 20, 2018 - Congress tackles the opioid epidemic. But how much will it help?
March 20, 2018 - Neanderthals Just Part of the Evolutionary Puzzle
March 20, 2018 - Higher Mortality With Surgery for Early NSCLC
March 20, 2018 - Researchers go skin deep to explore what causes wrinkles
March 20, 2018 - E-cigarette use linked to fat accumulation in the liver
March 20, 2018 - Fearful worms provide new clues about human anxiety
March 20, 2018 - Oral micronized progesterone may reduce hot flashes, night sweats in perimenopausal women
March 20, 2018 - Newer treatment for type 2 diabetes reduces liver fat in patients with NAFLD
March 20, 2018 - I.D. Break: PrEP Map; Faulty Flu Meds; Better Zika Test?
March 20, 2018 - Bronchial thermoplasty can improve severe asthmatic cough
March 19, 2018 - Speeding up wound healing using nanofiber dressings
March 19, 2018 - Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
March 19, 2018 - Optimizing Sham Acupuncture: That’s Improbable!
March 19, 2018 - Women who have gestational diabetes in pregnancy are at higher risk of future health issues
March 19, 2018 - Viagra cuts colorectal cancer risk in animal model
March 19, 2018 - Vitamin B12 supplementation could postpone disease progression in Parkinson’s patients
March 19, 2018 - Study shows that omega-6 fatty acids could protect against premature death
March 19, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
March 19, 2018 - Minorities More Sensitive To Pain? Pain Medicine News Report
March 19, 2018 - Low blood sugar poses unaddressed threat to people with type 2 diabetes
March 19, 2018 - ACEA goes live with exhaustive, searchable library of NovoCyte publications
March 19, 2018 - Consumption of low-calorie sweeteners could promote metabolic syndrome, increase diabetes risk
March 19, 2018 - Wearable medical patch shows promise for early detection of hypoglycemia in type 1 diabetes
March 19, 2018 - High-energy breakfast leads to better diabetes control and weight loss
March 19, 2018 - D.C. Week: Community Health Centers Get Azar’s Love
March 19, 2018 - Younger siblings of SIDS victims have four-fold increased risk of sudden death
March 19, 2018 - Toothpaste alone does not prevent dental erosion or hypersensitivity
March 19, 2018 - Discovery aids understanding of amyotrophic lateral sclerosis
March 19, 2018 - Hormone imbalance may be reason for higher diabetes rates among men with insufficient sleep
March 19, 2018 - Docs worry there’s ‘nowhere to send’ new and expectant moms with depression
March 19, 2018 - Obesity linked to increased DNA damage in breast epithelium of BRCA mutation carriers
March 19, 2018 - Heart rate increases with higher alcohol consumption
March 19, 2018 - Template produced for clinically validated DIY stethoscope
March 19, 2018 - Experts highlight nocturia as most common cause of poor night’s sleep
March 19, 2018 - Fit Middle-Aged Women May Fend Off Dementia Later
March 19, 2018 - Fake Insta Doc; Humana’s Weird Pay Bump Tax Trick; Few NPDB Searches
March 19, 2018 - Guidelines for fluoride intake—are they appropriate?
March 19, 2018 - Race and pre-pregnancy BMI may be key predictors of maternal weight gain
March 19, 2018 - Telediabetes program improves blood sugar control for veterans
March 19, 2018 - Research suggests breastfeeding as protective factor against obesity in high-birthweight infants
March 19, 2018 - Morning Break: House Nixes ‘Right-to-Try’ Bill; Purdue’s PR Makeover; Air in the Brain
March 19, 2018 - Heart researchers develop a new, promising imaging technique for cardiac arrhythmias
March 19, 2018 - Mice study shows how BPA exposure during pregnancy can lead to altered brain development
March 19, 2018 - Breastfeeding mothers who overeat may increase risk of health problems in offspring
March 19, 2018 - New mobile application can detect atrial fibrillation that causes strokes
March 19, 2018 - Study finds low rates of preconception counseling among women of childbearing age with diabetes
March 19, 2018 - Vitl Life Science Solutions announces launch of new Lu-mini at analytica 2018
March 19, 2018 - ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
March 19, 2018 - D.C. Week: States Plead for Federal $$ in Opioid Fight
March 19, 2018 - Polycystic ovary syndrome – Genetics Home Reference
March 19, 2018 - Reducing co-payments improves patient, physician adherence to guideline-recommended treatment post-MI
March 19, 2018 - Normalizing estrogen levels can benefit female athletes with irregular menstrual periods
March 19, 2018 - Fitness trackers and virtual coaches motivate patients to exercise post cardiac rehab
March 19, 2018 - Atrial fibrillation patients could reduce risk of dementia by taking stroke prevention drugs
March 19, 2018 - Low sperm count more prevalent with other health problems finds study
March 19, 2018 - Male birth control pill taken once a day shows success
March 19, 2018 - AcelRx Announces Receipt of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA New Drug Application in Q2 2018
March 19, 2018 - Eye Docs Adopt EHRs Despite Reservations
March 19, 2018 - CRISPR enhances cancer immunotherapy
March 19, 2018 - Study finds first evidence of delayed aging among Americans
March 19, 2018 - Aussies unaware of sun protection rules to prevent skin cancer
March 19, 2018 - Essential oils linked to abnormal breast development in boys
March 19, 2018 - ‘Tummy Tuck’ Relieved Postpartum Back Pain/Incontinence
Triple Therapy Improves PFS in Certain Breast Ca Patients

Triple Therapy Improves PFS in Certain Breast Ca Patients

image_pdfDownload PDFimage_print

Action Points

  • Dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib (Tykerb) and trastuzumab (Herceptin) + an aromatase inhibitor (AI) improved progression-free survival (PFS) versus single HER2 blockade in HER2-positive/hormone receptor (HR)-positive metastatic breast cancer.
  • Note that HER2–positive breast cancer (BC) constitutes approximately 20% to 25% of BC and is associated with poor prognosis,and approximately 50% of HER2-positive BCs are HR-positive, so HER2-positive/HR-positive represent roughly 10% of all BCs.

Targeting HER2 with two agents — lapatinib (Tykerb) and trastuzumab (Herceptin) — and adding an aromatase inhibitor (AI) significantly improved progression-free survival (PFS) compared to trastuzumab/AI in patients with HER2-positive and hormone receptor-positive metastatic breast cancer, researchers found.

Results from the large, randomized, phase III ALTERNATIVE trial demonstrated that the combination of lapatinib/trastuzumab/AI provided a clinically meaningful prolongation of PFS compared with trastuzumab/AI with a median PFS of 11.0 versus 5.7 months, respectively, according to Stephen R.D. Johnston, MA, PhD, of The Royal Marsden NHS Foundation Trust in London, and colleagues.

This represented a statistically significant 38% reduction in the risk of disease progression (hazard ratio [HR] 0.62; P=0.0064) in patients not suitable for chemotherapy, the study authors reported online in the Journal of Clinical Oncology. Lapatinib/trastuzumab/AI was also relatively well tolerated compared with trastuzumab/AI.

These findings indicate that patients with HER2-positive/HR-positive MBC who are not candidates for chemotherapy can be adequately treated with dual HER2 blockade plus an AI, Johnston and colleagues emphasized. “Although survival data were immature, there was also a trend in favor of the dual-blockade treatment (median 46.0 versus 40.0 months),” they wrote.

The PFS benefit of lapatinib/trastuzumab/AI compared with trastuzumab/AI was consistent across patient subgroups. The overall response rate (ORR) and clinical benefit rate (CBR) also favored the lapatinib/trastuzumab/AI combination over trastuzumab/AI (ORR 31.7% versus 13.7%, and CBR 41% versus 31%, respectively).

“Dual HER2 blockade enhances clinical benefit versus single HER2 blockade,” the study authors noted. “The use of dual anti-HER2 blockade represents a potential strategy to further improve the outcome of these patients,” Johnston and colleagues added.

The ALTERNATIVE trial enrolled 355 postmenopausal women from 112 sites in 29 countries. All patients had received prior endocrine therapy and experienced disease progression after prior neo(adjuvant)/first-line trastuzumab plus chemotherapy. Patients were randomly assigned 1:1:1 to lapatinib/trastuzumab/AI, trastuzumab/AI, or lapatinib/AI.

In the lapatinib/trastuzumab/AI arm, patients took 1,000 mg/day oral lapatinib. In the lapatinib/AI arm, patients took 1,500 mg/day. In both trastuzumab arms, patients received an IV loading dose of 8 mg/kg trastuzumab followed by a maintenance dose of 6 mg/kg every 3 weeks. Oral AIs included letrozole (Femara; 2.5 mg/day), antinuclear antibodies (1 mg/day), or exemestane (Aromasin; 25 mg/day).

The median PFS with lapatinib/AI versus trastuzumab/AI was 8.3 versus 5.7 months (HR 0.71; P=0.0361).

Common adverse events were seen in lapatinib/trastuzumab/AI; trastuzumab/AI; and lapatinib/AI, respectively, and included:

  • Diarrhea (69%, 9%, and 51%)
  • Rash (36%, 2%, and 28%)
  • Nausea (22%, 9%, and 22%)
  • Paronychia (30%, 0%, and 15%)

Frequency of adverse events, mostly grade 1 or 2, was 92% in the two lapatinib arms and 74% in the trastuzumab arm. Serious AEs were reported across the three study groups, with discontinuation lowest in the lapatinib/trastuzumab/AI arm (3%) compared to the trastuzumab/AI (6%) and lapatinib/AI (9%) arms.

Other studies looking at HER2 blockade have been conducted in different patient populations, so “cross-trial comparisons need to be interpreted with caution,” the study authors warned. Although the PFS outcome in ALTERNATIVE lines up with results from other studies, there are a limited number of trials designed for patients with HER2-positive/HR-positive metastatic breast cancer, they pointed out.

In the phase II PERTAIN study of locally advanced or metastatic hormone receptor-positive HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab and an AI in the first-line setting significantly improved PFS by 3 months. The median PFS was 18.9 months with pertuzumab, trastuzumab and endocrine therapy compared to 15.80 months with trastuzumab plus endocrine therapy.

However, only 77% of patients were trastuzumab-naive and 55% of patients had received induction chemotherapy in this first-line setting, the ALTERNATIVE study authors noted.

The rationale for PERTAIN came from the TAnDEM study, which showed that adding trastuzumab to anastrozole (Arimidex) significantly improved PFS over anastrozole alone. The CLEOPATRA study also demonstrated improved PFS and OS with the addition of pertuzumab to trastuzumab plus docetaxel.

These findings contrast the lack of benefit observed with lapatinib in the adjuvant setting in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial, Johnston and colleagues pointed out. In addition, the APHINITY trial demonstrated only a modest benefit with pertuzumab.

“This discrepancy may be the result, at least in part, of the excellent outcome with adjuvant single HER2 blockade with TRAS, making the demonstration of additional benefit with dual blockade harder. Dual HER2 blockade may benefit only a small subset of high-risk patients,” they suggested.

Similarly, results from an earlier international trial showed that adjuvant therapy with two HER2-targeted drugs failed to improve disease-free survival in early breast cancer compared with trastuzumab monotherapy. Concurrent administration of lapatinib and trastuzumab resulted in a nonsignificant 16% reduction in DFS compared with trastuzumab alone.

However, in a nonrandomized phase II study, the combination of lapatinib and trastuzumab was effective and well-tolerated in patients with HER2+ breast cancer who had received up to two lines of therapy for advanced disease. The study also showed that metabolic imaging appeared to be helpful for selecting poor responders in advance, thus sparing them the toxicity of chemotherapy.

Original funding for the ALTERNATIVE study was provided by GlaxoSmithKline. As of March 2, 2015, lapatinib was acquired by Novartis, the current sponsor of this study. Johnston reported relationships with Novartis, Eli Lilly, AstraZeneca, OBI Pharma, Puma Biotechnology, and Pfizer. A number of study co-authors also reported relationships with industry, including GlaxoSmithKline and Novartis.


Tagged with:

About author

Related Articles